Atherothrombosis Clinical Trial
Official title:
Pharmacogenomics of Antiplatelet Response - II
This clinical trial is examining the effect of 4-week aspirin therapy on platelet transcriptome in persons at high-risk for myocardial infarction or stroke due to family history of early-onset coronary artery disease.
Platelet aggregation can initiate thrombosis on ulcerated arterial plaques resulting in acute coronary syndrome (ACS). There is large variation in platelet aggregation between individuals. As the genetic message to the cell machinery is conveyed through its transcriptome, we hypothesize that much of the variability in platelet function can be explained by transcriptome changes including differences in gene or isoform expression, altered splicing events, or allele-specific expression. Moreover, aspirin modifies gene expression in several cells, but whether it also affects platelet transcriptome has not yet been studied. Our goal is to characterize the platelet transcriptome and identify genes that are up- or down-regulated after 4-week aspirin therapy. A major strength of our study is that it enrolls individuals from European Americans and African Americans and thus will have the ability to study similarities and differences between the two. The study will produce innovative comparative genomic/platelet phenotype data and will provide a potential pharmacogenomic and diagnostic template for the future discovery of novel antiplatelet regimens to prevent thrombosis-related cardiovascular disease events. ;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Completed |
NCT02616497 -
ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)
|
Phase 4 | |
Not yet recruiting |
NCT02898467 -
Atherothrombosis Markers in Diabetics
|
N/A | |
Completed |
NCT01225562 -
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
|
Phase 3 | |
Completed |
NCT03943966 -
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer
|
N/A | |
Completed |
NCT01805063 -
Effect of Fire Suppression and Emergency Duties on Vascular Function
|
||
Terminated |
NCT01788930 -
Aspirin Resistance and Sleep Apnea in Type-2 Diabetic Patients
|
N/A | |
Recruiting |
NCT03062319 -
Optimal Antithrombotic Therapy in Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation and Atherothrombosis
|
Phase 4 | |
Completed |
NCT01812317 -
Effect of Real-fire Training on Vascular Function
|
N/A | |
Completed |
NCT01813032 -
Comparison of Vascular Function in Emergency Service Professionals
|